3-氟-4,5-二甲氧基苯甲醛 | 71924-61-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟-4,5-二甲氧基苯甲醛
• 英文名称: 3-fluoro-4,5-dimethoxybenzaldehyde
• 英文别名: 5-fluoroveratraldehyde
• CAS: 71924-61-3
• 化学式: C₉H₉FO₃
• 分子量: 184.167
• InChiKey: KMWSZQLJNRHQES-UHFFFAOYSA-N

物化性质

• 熔点：
  51-53 °C
• 沸点：
  266.6±35.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  3-氟-4,5-二甲氧基苯甲醛 在 盐酸 、 ammonium acetate 、 锌 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 1.5h， 生成 3,4-dimethoxy-5-fluorophenethylamine
  参考文献：
  名称：

  Chemoselective Zinc/HCl Reduction of Halogenated β-Nitrostyrenes: Synthesis of Halogenated Dopamine Analogues

  摘要：

  A detailed account regarding the synthesis of 2- and 5-halogenated dopamine is given. The key step is a chemoselective reduction of a nitrostyrene by Zn/HCl at 0 degrees C. These conditions represent a simple, low-cost alternative to reduction by water-sensitive hydride donors and two-step procedures. Under these conditions, aryl fluoride, chloride, and bromide groups are stable. However, iodine undergoes significant reductive dehalogenation.

  DOI：

  10.1055/s-0034-1379481
• 作为产物：
  描述：

  间氟苯甲醚 在 盐酸 、 正丁基锂 、 乌洛托品 、 四丁基硫酸氢铵 、 溶剂黄146 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 17.5h， 生成 3-氟-4,5-二甲氧基苯甲醛
  参考文献：
  名称：

  Chemoselective Zinc/HCl Reduction of Halogenated β-Nitrostyrenes: Synthesis of Halogenated Dopamine Analogues

  摘要：

  A detailed account regarding the synthesis of 2- and 5-halogenated dopamine is given. The key step is a chemoselective reduction of a nitrostyrene by Zn/HCl at 0 degrees C. These conditions represent a simple, low-cost alternative to reduction by water-sensitive hydride donors and two-step procedures. Under these conditions, aryl fluoride, chloride, and bromide groups are stable. However, iodine undergoes significant reductive dehalogenation.

  DOI：

  10.1055/s-0034-1379481

文献信息

• IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.

  公开号：US20160158243A1

  公开（公告）日：2016-06-09

  The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.

  本发明提供了作为胰岛素/IGF信号调节剂的化合物，用于治疗神经退行性疾病和紊乱。该发明提供了包括这些化合物的药物组合物，以及利用这些化合物和组合物治疗神经退行性疾病的方法，特别是由蛋白毒性引起的神经退行性疾病，如阿尔茨海默病。
• [EN] COMPLEMENT PATHWAY MODULATORS AND USES THEREOF<br/>[FR] MODULATEUR DE LA VOIE D'ACTIVATION DU COMPLÉMENT ET SES UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2013192345A1

  公开（公告）日：2013-12-27

  The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种化合物I的方法，用于制造该发明的化合物，并且作为抑制补体替代途径的治疗用途，特别是作为抑制因子B的治疗用途，例如用于治疗年龄相关性黄斑变性和糖尿病视网膜病变。本发明还提供了一种药理活性剂的组合和一种制药组合物。
• RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：The Johns Hopkins University

  公开号：US20210094933A1

  公开（公告）日：2021-04-01

  The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

  本公开提供了受免疫蛋白配体家族FK506和雷帕霉素天然产物启发的大环化合物。生成包含FK506和雷帕霉素结合结构域的Rapafucin大环化合物库，应具有作为治疗疾病新药的潜力。
• Halocombstatins and methods of synthesis thereof
  申请人：Pettit R. George

  公开号：US20050176688A1

  公开（公告）日：2005-08-11

  The invention relates to novel compounds denominated halocombstatins. The halocombstatins are derivatives of combretastatin A-3, and include compounds that exhibit cancer growth cell inhibition against a panel of human cancer cell lines and the murine P388 leukemia, as well as activity as inhibitors of tubulin polymerization and inhibitors of the binding of colchicine to tubulin.

  这项发明涉及一种名为卤化康柏斯塔汀（halocombstatins）的新化合物。卤化康柏斯塀是康柏斯塀A-3的衍生物，包括对一系列人类癌细胞系和小鼠P388白血病表现出癌细胞生长抑制作用的化合物，以及作为微管聚合抑制剂和结合秋水仙碱对微管的抑制剂的活性。
• Syntheses and adrenergic agonist properties of ring-fluorinated isoproterenols
  作者：Kenneth L. Kirk、Daniele Cantacuzene、Brian Collins、George T. Chen、Yuth Nimit、Cyrus R. Creveling

  DOI：10.1021/jm00348a014

  日期：1982.6

  formed between the corresponding ring-fluorinated 3,4-bis(benzyloxy)phenethanolamine and acetone, followed by reductive debenzylation in the presence of oxalic acid to yield crystalline neutral oxalates. The apparent beta-adrenergic potencies were determined in the isolated guinea pig atria. 2-Fluoro- and 5-fluoroisoproterenol were equipotent with (+/-)-isoproterenol, while 6-fluoroisoprotenol was virtually

  通过还原相应的环氟化3,4-双（苄氧基）苯乙醇胺和丙酮之间形成的席夫碱，然后在草酸存在下进行还原性脱苄基反应，合成2-氟-，5-氟-和6-氟异丙基肾上腺素。酸产生结晶的中性草酸酯。在分离的豚鼠心房中确定了明显的β-肾上腺素能。2-氟和5-氟异丙肾上腺素与（+/-）-异丙肾上腺素等效，而6-氟异丙肾上腺素实际上是无活性的。任何氟代异丙肾上腺素均未显示出α-肾上腺素能激动剂活性（豚鼠主动脉）。氟异丙肾上腺素从大鼠脑分离的膜制剂中置换出α-和β-特异性放射性配体与器官制剂的反应一致。从而，明显的氟诱导的特异性是由于受体结合位点的特异性。讨论了氟取代的影响，涉及6-氟取代基对异丙肾上腺素β-激动剂性能的明显负面影响，由于2-氟取代基引起的效力缺乏任何增加以及氟-取代的可能性诱导芳环电子密度的变化，这可能是氟代异丙肾上腺素和氟去甲肾上腺素的氟诱导的特异性的合理原因。